Simplified Meal Announcement Versus Precise Carbohydrate Counting in Adolescents With Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed Loop System: A Randomized Controlled Trial Comparing Glucose Control

Goran Petrovski, Judith Campbell, Maheen Pasha, Emma Day, Khalid Hussain, Amel Khalifa, Tim van den Heuvel, Goran Petrovski, Judith Campbell, Maheen Pasha, Emma Day, Khalid Hussain, Amel Khalifa, Tim van den Heuvel

Abstract

Objective: We aimed to compare glucose control in adolescents with type 1 diabetes (T1D) using the MiniMed 780G system who used simplified meal announcement with those who used precise carbohydrate counting.

Research design and methods: This randomized controlled trial included 34 participants (age 12-18 years) with T1D who were on multiple daily injections or insulin pump and were scheduled to start using the MiniMed 780G system at Sidra Medicine in Qatar. After a 7-day run-in period, participants were randomly assigned to the fix group (simplified meal announcement by preset of three personalized fixed carbohydrate amounts) or the flex group (precise carbohydrate counting) and followed for 12 weeks. Between-group difference in time in range (TIR) was the primary end point. Secondary end points included HbA1c and other glycometrics.

Results: During the 12-week study phase, TIR was 73.5 ± 6.7% in the fix and 80.3 ± 7.4% in the flex group, with a between-group difference of 6.8% in favor of flex (P = 0.043). Time >250 mg/dL was better in the flex group (P = 0.012), whereas HbA1c (P = 0.168), time below range (P = 0.283), and time between 180 and 250 mg/dL (P = 0.114) did not differ.

Conclusions: Adolescents using the MiniMed 780G system with a preset of three personalized fixed carbohydrate amounts can reach international targets of glycemic control. Therefore, it may be a valuable alternative to precise carbohydrate counting in users who are challenged by precise carbohydrate counting. Because carbohydrate counting further improves outcomes, these skills remain important for MiniMed 780G users.

© 2023 by the American Diabetes Association.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Study design and enrollment scheme.
Figure 2
Figure 2
TIR during different study periods. Data are percentage of TIR during the interval. Glucose values

References

    1. Mehta SN, Quinn N, Volkening LK, Laffel LM. Impact of carbohydrate counting on glycemic control in children with type 1 diabetes. Diabetes Care 2009;32:1014–1016
    1. Brazeau AS, Mircescu H, Desjardins K, et al. . Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Res Clin Pract 2013;99:19–23
    1. Builes-Montaño CE, Ortiz-Cano NA, Ramirez-Rincón A, Rojas-Henao NA. Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials. J Hum Nutr Diet 2022;35:1030–1042
    1. Bell KJ, Barclay AW, Petocz P, Colagiuri S, Brand-Miller JC. Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2014;2:133–140
    1. Ruan Y, Thabit H, Leelarathna L, et al. .; AP@home Consortium . Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes. Diabetes Care 2016;39:830–832
    1. Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther 2021;23:601–608
    1. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al. .; iDCL Trial Research Group . Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technol Ther 2021;23:342–349
    1. Bergenstal RM, Nimri R, Beck RW, et al. .; FLAIR Study Group . A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 2021;397:208–219
    1. Silva JD, Lepore G, Battelino T, et al. . Real-world performance of the MiniMed™ 780G system: first report of outcomes from 4120 users. Diabetes Technol Ther 2022;24:113–119
    1. Petrovski G, Al Khalaf F, Campbell J, et al. . Successful transitioning children and adolescents with type 1 diabetes from multiple daily injections to advanced hybrid closed-loop system in 10 days: a prospective intervention study on MiniMed 780G system. Acta Diabetol 2022;59:743–746
    1. Beato-Víbora PI, Gallego-Gamero F, Ambrojo-López A, Gil-Poch E, Martín-Romo I, Arroyo-Díez FJ. Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 2021;23:609–615
    1. Petrovski G, Al Khalaf F, Campbell J, Fisher H, Umer F, Hussain K. 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol 2020;57:681–687
    1. Arrieta A, Battelino T, Scaramuzza AE, et al. . Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: evidence from 12 870 real-world users. Diabetes Obes Metab 2022;24:1370–1379
    1. Battelino T, Danne T, Bergenstal RM, et al. . Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593–1603
    1. Tornese G, Carletti C, Giangreco M, Nisticò D, Faleschini E, Barbi E. Carbohydrate tolerance threshold for unannounced snacks in children and adolescents with type 1 diabetes using an advanced hybrid closed-loop system. Diabetes Care 2022;45:1486–1488
    1. Smart CE, Annan F, Higgins LA, Jelleryd E, Lopez M, Acerini CL. ISPAD clinical practice consensus guidelines 2018: nutritional management in children and adolescents with diabetes. Pediatr Diabetes 2018;19(Suppl. 27):136–154
    1. Carlson AL, Sherr JL, Shulman DI, et al. . Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 2022;24:178–189
    1. Castañeda J, Mathieu C, Aanstoot HJ, et al. . Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes Metab 2022;24:2212–2221
    1. Abildgaard A, Knudsen CS, Bjerg LN, Lund S, Støy J. Lot variation and inter-device differences contribute to poor analytical performance of the DCA Vantage™ HbA1c POCT instrument in a true clinical setting. Clin Chem Lab Med 2021;60:127–134
    1. Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem 2010;56:44–52

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj